Lorlatinib was approved for the treatment of anaplastic lymphoma kinase- or c-ros oncogene 1-positive NSCLC based on the CROWN Trial (NCT03052608), but 72% of patients developed hypercholesterolemia with the majority necessitating statin treatment.46 This evidence concerns the gene ALK and familial hypercholesterolemia.